Autolus Therapeutics (AUTL) FCF Margin (2017 - 2025)
Autolus Therapeutics (AUTL) posted quarterly FCF Margin of 273.53% for Q4 2025, up 16885061.0% year-on-year from N/an in Q4 2024, and up 19.82% on a QoQ basis from 341.17% in Q3 2025.
Autolus Therapeutics (AUTL) FCF Margin (2017 - 2025) Analysis & Trends
Autolus Therapeutics (AUTL) has reported FCF Margin for 9 consecutive years, with 273.53% the latest figure, recorded in Q4 2025.
- Quarterly FCF Margin rose 16885061.0% year-over-year to 273.53% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 401.4% (up 185297.0% YoY) and the FY2025 annual result came in at 401.4%, up 185498.0% from the prior year.
- FCF Margin rose to 273.53% in Q4 2025 per AUTL's latest filing, from 341.17% in the prior quarter.
- Over the last five years, FCF Margin for AUTL reached as high as 273.53% in Q4 2025 and fell as low as 169124.14% in Q4 2024.
- A 5-year average of 17309.17% and a median of 2049.91% in 2022 frame the typical range for FCF Margin.
- Annual changes were most pronounced in 2023 — FCF Margin sank 869733 bps — and 2025, when it jumped 16885061 bps.
- Year by year, FCF Margin stood at 16360.17% in 2021, then surged by 97 bps to 415.39% in 2022, then slumped by 2372 bps to 10267.49% in 2023, then plunged by 1547 bps to 169124.14% in 2024, then surged by 100 bps to 273.53% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 273.53%, 341.17%, and 382.63% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Autolus Therapeutics | 404.53 Mn | 103.82 Mn | -1.04 Mn | -273.53% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -273.53% |
| Sep 30, 2025 | -341.17% |
| Jun 30, 2025 | -382.63% |
| Mar 31, 2025 | -933.07% |
| Dec 31, 2024 | -169,124.14% |
| Mar 31, 2024 | -406.62% |
| Sep 30, 2023 | -10,267.49% |
| Mar 31, 2023 | -3,568.96% |
| Dec 31, 2022 | -415.39% |
| Sep 30, 2022 | -1,570.16% |
| Mar 31, 2022 | -21,566.87% |
| Sep 30, 2021 | -16,360.17% |
| Jun 30, 2021 | -2,529.66% |
| Mar 31, 2021 | -14,588.48% |
| Dec 31, 2020 | -8,218.32% |
| Sep 30, 2020 | -9,842.69% |
| Jun 30, 2020 | -9,375.09% |
| Mar 31, 2020 | -8,478.40% |
| Jun 30, 2019 | -2,463.21% |
| Mar 31, 2019 | -1,723.37% |